Logo image of RIGL

RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

NASDAQ:RIGL - Nasdaq - US7665597024 - Common Stock - Currency: USD

20.09  -0.74 (-3.55%)

After market: 20.09 0 (0%)

Fundamental Rating

5

Overall RIGL gets a fundamental rating of 5 out of 10. We evaluated RIGL against 572 industry peers in the Biotechnology industry. There are concerns on the financial health of RIGL while its profitability can be described as average. RIGL is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
RIGL had negative earnings in each of the past 5 years.
In the past 5 years RIGL reported 4 times negative operating cash flow.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of RIGL (2.78%) is better than 93.78% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.82%, RIGL belongs to the top of the industry, outperforming 95.20% of the companies in the same industry.
Industry RankSector Rank
ROA 2.78%
ROE N/A
ROIC 8.82%
ROA(3y)-25.25%
ROA(5y)-29.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300 400

1.3 Margins

Looking at the Profit Margin, with a value of 2.46%, RIGL belongs to the top of the industry, outperforming 93.78% of the companies in the same industry.
RIGL's Operating Margin of 6.03% is amongst the best of the industry. RIGL outperforms 94.67% of its industry peers.
RIGL has a better Gross Margin (89.43%) than 92.72% of its industry peers.
In the last couple of years the Gross Margin of RIGL has remained more or less at the same level.
Industry RankSector Rank
OM 6.03%
PM (TTM) 2.46%
GM 89.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5Y-1.11%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

RIGL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, RIGL has less shares outstanding
The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
RIGL has a worse debt/assets ratio than last year.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

RIGL has an Altman-Z score of -10.87. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.87, RIGL is not doing good in the industry: 75.84% of the companies in the same industry are doing better.
RIGL has a debt to FCF ratio of 5.77. This is a neutral value as RIGL would need 5.77 years to pay back of all of its debts.
RIGL has a better Debt to FCF ratio (5.77) than 93.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 5.77
Altman-Z -10.87
ROIC/WACC0.89
WACC9.91%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

RIGL has a Current Ratio of 1.96. This is a normal value and indicates that RIGL is financially healthy and should not expect problems in meeting its short term obligations.
RIGL's Current ratio of 1.96 is on the low side compared to the rest of the industry. RIGL is outperformed by 76.73% of its industry peers.
A Quick Ratio of 1.87 indicates that RIGL should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.87, RIGL is not doing good in the industry: 76.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.87
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 110.00%, which is quite impressive.
Looking at the last year, RIGL shows a quite strong growth in Revenue. The Revenue has grown by 18.97% in the last year.
The Revenue has been growing by 21.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)110%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)18.97%
Revenue growth 3Y2.48%
Revenue growth 5Y21.3%
Sales Q2Q%96.58%

3.2 Future

RIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.54% yearly.
Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 19.19% on average per year.
EPS Next Y126.45%
EPS Next 2Y66.16%
EPS Next 3Y48.45%
EPS Next 5Y24.54%
Revenue Next Year49.74%
Revenue Next 2Y31.65%
Revenue Next 3Y25.75%
Revenue Next 5Y19.19%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8 -10

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 143.50, which means the current valuation is very expensive for RIGL.
Based on the Price/Earnings ratio, RIGL is valued cheaply inside the industry as 92.36% of the companies are valued more expensively.
RIGL is valuated expensively when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 17.60, which indicates a rather expensive current valuation of RIGL.
95.03% of the companies in the same industry are more expensive than RIGL, based on the Price/Forward Earnings ratio.
RIGL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.68.
Industry RankSector Rank
PE 143.5
Fwd PE 17.6
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaply inside the industry as 94.67% of the companies are valued more expensively.
RIGL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RIGL is cheaper than 95.03% of the companies in the same industry.
Industry RankSector Rank
P/FCF 34.19
EV/EBITDA 31.21
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
RIGL's earnings are expected to grow with 48.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.13
PEG (5Y)N/A
EPS Next 2Y66.16%
EPS Next 3Y48.45%

More info and screens

0

5. Dividend

5.1 Amount

RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (2/21/2025, 8:00:01 PM)

After market: 20.09 0 (0%)

20.09

-0.74 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners69.99%
Inst Owner Change4.06%
Ins Owners2.63%
Ins Owner Change7.55%
Market Cap353.99M
Analysts76.67
Price Target31.11 (54.85%)
Short Float %3.27%
Short Ratio2.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)578.2%
Min EPS beat(2)79.86%
Max EPS beat(2)1076.54%
EPS beat(4)3
Avg EPS beat(4)296.59%
Min EPS beat(4)-70.03%
Max EPS beat(4)1076.54%
EPS beat(8)7
Avg EPS beat(8)177.87%
EPS beat(12)10
Avg EPS beat(12)122.06%
EPS beat(16)13
Avg EPS beat(16)365.55%
Revenue beat(2)2
Avg Revenue beat(2)18.7%
Min Revenue beat(2)8.08%
Max Revenue beat(2)29.32%
Revenue beat(4)3
Avg Revenue beat(4)8.21%
Min Revenue beat(4)-7.45%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)15.34%
Revenue beat(12)8
Avg Revenue beat(12)10.7%
Revenue beat(16)10
Avg Revenue beat(16)18.76%
PT rev (1m)-2.66%
PT rev (3m)17.68%
EPS NQ rev (1m)22%
EPS NQ rev (3m)95.53%
EPS NY rev (1m)35.38%
EPS NY rev (3m)211.25%
Revenue NQ rev (1m)5.64%
Revenue NQ rev (3m)5.03%
Revenue NY rev (1m)1.59%
Revenue NY rev (3m)9.46%
Valuation
Industry RankSector Rank
PE 143.5
Fwd PE 17.6
P/S 2.25
P/FCF 34.19
P/OCF 33.01
P/B N/A
P/tB N/A
EV/EBITDA 31.21
EPS(TTM)0.14
EY0.7%
EPS(NY)1.14
Fwd EY5.68%
FCF(TTM)0.59
FCFY2.93%
OCF(TTM)0.61
OCFY3.03%
SpS8.94
BVpS-0.83
TBVpS-2.4
PEG (NY)1.13
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.78%
ROE N/A
ROCE 11.17%
ROIC 8.82%
ROICexc 31.29%
ROICexgc N/A
OM 6.03%
PM (TTM) 2.46%
GM 89.43%
FCFM 6.58%
ROA(3y)-25.25%
ROA(5y)-29.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5Y-1.11%
F-Score5
Asset Turnover1.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 5.77
Debt/EBITDA 5.24
Cap/Depr 19.35%
Cap/Sales 0.23%
Interest Coverage 1.36
Cash Conversion 93.96%
Profit Quality 266.81%
Current Ratio 1.96
Quick Ratio 1.87
Altman-Z -10.87
F-Score5
WACC9.91%
ROIC/WACC0.89
Cap/Depr(3y)436.98%
Cap/Depr(5y)340.62%
Cap/Sales(3y)4.54%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)110%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y126.45%
EPS Next 2Y66.16%
EPS Next 3Y48.45%
EPS Next 5Y24.54%
Revenue 1Y (TTM)18.97%
Revenue growth 3Y2.48%
Revenue growth 5Y21.3%
Sales Q2Q%96.58%
Revenue Next Year49.74%
Revenue Next 2Y31.65%
Revenue Next 3Y25.75%
Revenue Next 5Y19.19%
EBIT growth 1Y149.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year167.73%
EBIT Next 3Y63.85%
EBIT Next 5YN/A
FCF growth 1Y114.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y115.12%
OCF growth 3YN/A
OCF growth 5YN/A